Seratrodast

HCID 2449CAS 112665-43-7

Teilstruktursuche Ähnliche Strukturen suchen

Grundinformationen

Standard-SMILES: CC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O
InChIKey: ZBVKEHDGYSLCCC-UHFFFAOYSA-N
Summenformel: C22H26O4
Durchschnittliche Molmasse: 354,4 g/mol
Monoisotopische Masse: 354,18310931

Überblick

Seratrodast is an organic molecular entity.

Namen und Bezeichner

Bevorzugter Name: Seratrodast
IUPAC: 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
Englischer Name: Seratrodast
Summenformel: C22H26O4
Molmasse: 354.44

Namen und Synonyme

SERATRODAST112665-43-7Bronica7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acidAbbott 73001AA-2414ABT-001Abbott-73001A-73001NSC-7596404U58JM421NBenzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+-)-

Weitere Namen anzeigen

CS-324BronicSeretraSerabenastCCRIS 893950MG/200MG/1G

7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acidseratrodastumRefChem:884908R03DX06692-169-8(+-)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid103185-78-0MFCD00875701

Datenbank-Bezeichner

CAS: 112665-43-7
PubChem CID: 2449
DTXSID: DTXSID4021397
ChEMBL: CHEMBL70972
ChEBI: CHEBI:32126
UNII: 4U58JM421N
EC Number: 692-169-8
Nikkaji: J1.633.058B

Eigenschaften

Berechnete Struktureigenschaften

XLogP: 4,4
Polarare Oberfläche (TPSA): 71,4 Å²
H-Brücken-Donoren: 1
H-Brücken-Akzeptoren: 4
Frei drehbare Bindungen: 8
Schwere Atome: 26
Formalladung: 0
Komplexität: 633

Physikochemische Eigenschaften

Schmelzpunkt: 118 · 118-120°C
Siedepunkt: 522.3 · 522.3±49.0 °C(Predicted)
Dichte: 1.14 · 1.140±0.06 g/cm3(Predicted)
storage temp.: -20 °C · Sealed in dry,Store in freezer, under -20°C
Löslichkeit: Chloroform (Slightly), Methanol (Slightly)
pka: 4.76 · 4.76±0.10(Predicted)
Aggregatzustand: Yellow-orange solid.
Farbe: Pale Orange to Yellow
Merck: 14 · 14,8459
InChI: InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
InChIKey: ZBVKEHDGYSLCCC-UHFFFAOYSA-N
SMILES: C1(C)C(=O)C(C)=C(C(C2=CC=CC=C2)CCCCCC(=O)O)C(=O)C=1C
CAS Datenbank: 112665 · 112665-43-7(CAS DataBase Reference)

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Hazard Classes and CategoriesRepr. 2 (100%)

Sicherheitsdaten

wgk: WGK 3
hs_code: 2918.30.3000
RTECS-Nr.: DA1600050
Speicherklasse: 11 - Combustible Solids
Hazard Classifications: Repr. 2

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

R - Respiratory system

QR - Respiratory system

Metabolism/MetabolitesSeratrodast has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoyl]oxyoxane-2-carboxylic acid.

MeSH Pharmacological Classification · 3 Einträge

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds that inhibit the action of prostaglandins.

Drugs that are used to treat asthma.

Anwendungen · 1 Eintrag

BeschreibungSeratrodast, a novel benzoquinone derivative, is the first thromboxane A2 (TxA2) receptor antagonist to reach the market. It is orally active for the treatment of bronchospastic disorders such as asthma. TxA2, a metabolite of the arachidonate cascade, is involved in several cardiovascular and respiratory diseases through its potent biological effects on platelet aggregation and constriction of vascular and respiratory smooth muscles. Seratrodast potently inhibits platelet aggregation and bronchoconstriction induced by a TxA2 mimic and by a variety of spasmogenic prostanoids including PGF2α, PGD2 and 9α,11β-PGF2. Seratrodast shows excellent efficacy in asthma and has been reported to be potentially useful in hyper-responsive disorder. The R-(+)- seratrodast was reported to be the active isomer.